IN2014CN02152A - - Google Patents

Download PDF

Info

Publication number
IN2014CN02152A
IN2014CN02152A IN2152CHN2014A IN2014CN02152A IN 2014CN02152 A IN2014CN02152 A IN 2014CN02152A IN 2152CHN2014 A IN2152CHN2014 A IN 2152CHN2014A IN 2014CN02152 A IN2014CN02152 A IN 2014CN02152A
Authority
IN
India
Prior art keywords
metal salt
aureus
adsorbed
agonist
tlr agonist
Prior art date
Application number
Other languages
English (en)
Inventor
Fabio Bagnoli
Barbara Baudner
Simone Bufali
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014CN02152A publication Critical patent/IN2014CN02152A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IN2152CHN2014 2011-09-01 2012-08-31 IN2014CN02152A (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161530162P 2011-09-01 2011-09-01
US201261607999P 2012-03-07 2012-03-07
PCT/EP2012/067032 WO2013030378A1 (en) 2011-09-01 2012-08-31 Adjuvanted formulations of staphylococcus aureus antigens

Publications (1)

Publication Number Publication Date
IN2014CN02152A true IN2014CN02152A (sl) 2015-09-04

Family

ID=46763095

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2152CHN2014 IN2014CN02152A (sl) 2011-09-01 2012-08-31

Country Status (14)

Country Link
US (1) US20140363461A1 (sl)
EP (1) EP2763695A1 (sl)
JP (1) JP2014525429A (sl)
KR (1) KR20140066212A (sl)
CN (1) CN104093418A (sl)
AU (1) AU2012300765A1 (sl)
BR (1) BR112014004782A2 (sl)
CA (1) CA2847204A1 (sl)
IL (1) IL231104A0 (sl)
IN (1) IN2014CN02152A (sl)
MX (1) MX2014002363A (sl)
RU (1) RU2014112343A (sl)
SG (1) SG11201400210RA (sl)
WO (1) WO2013030378A1 (sl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010115175A1 (en) * 2009-04-03 2010-10-07 Momenta Pharmaceticals, Inc. Control of copolymer compositions
MX2012002723A (es) 2009-09-02 2012-04-11 Novartis Ag Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll.
WO2012031140A1 (en) 2010-09-01 2012-03-08 Novartis Ag Adsorption of immunopotentiators to insoluble metal salts
JP2014507142A (ja) 2011-02-08 2014-03-27 インテグレイテッド バイオセラピューティクス，インコーポレイテッド α溶血素オリゴペプチドを含む免疫原性組成物
EP2680885B8 (en) 2011-03-02 2018-07-25 GlaxoSmithKline Biologicals SA Combination vaccines with lower doses of antigen and/or adjuvant
US20140363461A1 (en) * 2011-09-01 2014-12-11 Fabio Bagnoli Adjuvanted formulations of staphylococcus aureus antigens
JP6325986B2 (ja) * 2012-03-07 2018-05-16 ノバルティス アーゲー 免疫学的に有用なアルギニン塩
EP2822581A2 (en) 2012-03-08 2015-01-14 Novartis AG Adjuvanted formulations of dtp booster vaccines
CN104684570A (zh) * 2012-08-31 2015-06-03 诺华股份有限公司 用于免疫抵抗金黄色葡萄球菌的稳定化的蛋白质
ES2737024T3 (es) * 2012-08-31 2020-01-09 Glaxosmithkline Biologicals Sa Proteínas estabilizadas para inmunización contra Staphylococcus aureus
JP2015528457A (ja) * 2012-08-31 2015-09-28 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
BE1022359B1 (fr) * 2014-03-17 2016-03-25 Glaxosmithkline Biologicals Sa Immunisation contre des infections staphylococciques des os et des articulations
WO2015144691A1 (en) * 2014-03-26 2015-10-01 Glaxosmithkline Biologicals Sa Compositions for immunising against staphylococcus aureus
AU2015238512B2 (en) 2014-03-26 2018-02-01 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
CN105646681B (zh) * 2016-01-21 2021-07-16 浙江海隆生物科技有限公司 一种奶牛金黄色葡萄球菌α-溶血素亚单位疫苗的制备方法及应用
WO2018009916A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
AR111760A1 (es) * 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
AU2020241686A1 (en) 2019-03-15 2021-11-04 Bolt Biotherapeutics, Inc. Immunoconjugates targeting HER2

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114787B1 (de) 1983-01-25 1991-09-25 Ciba-Geigy Ag Neue Peptidderivate
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
KR20060065643A (ko) 2003-07-24 2006-06-14 머크 앤드 캄파니 인코포레이티드 스타필로코쿠스 아우레우스에 대한 방어 면역 반응을유도하는 폴리펩타이드
US20060188515A1 (en) 2003-07-24 2006-08-24 Anderson Annaliesa S Polypeptides for inducing a protective immune response against staphylococcus aureus
CA2555342A1 (en) 2004-02-18 2005-09-01 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
TW200801003A (en) 2005-09-16 2008-01-01 Astrazeneca Ab Novel compounds
EP1939202A4 (en) 2005-09-22 2010-06-16 Dainippon Sumitomo Pharma Co NEW COMPOUND OF ADENINE
JPWO2007034916A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規アデニン化合物
WO2007034917A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規なアデニン化合物
EP1939198A4 (en) 2005-09-22 2012-02-15 Dainippon Sumitomo Pharma Co NEW ADENINE CONNECTION
TW200745114A (en) 2005-09-22 2007-12-16 Astrazeneca Ab Novel compounds
BRPI0707945A2 (pt) 2006-02-17 2011-05-17 Pfizer Ltd derivados de 3-deazapurina como modulares de tlr7
NZ574057A (en) 2006-06-12 2012-01-12 Glaxosmithkline Biolog Sa Staphylococcal antigen composition comprising an isolated S. aureus type 5 antigen; an isolated S. aureus type 8 antigen; an isolated S. aureus 336 antigen; an isolated S. aureus alpha-toxin antigen; and an isolated Staphylococcal leukocidin antigen
JP2009542645A (ja) 2006-07-05 2009-12-03 アストラゼネカ・アクチエボラーグ Ｔｌｒ７のモジュレーターとして作用する８−オキソアデニン誘導体
JP5356228B2 (ja) 2006-07-07 2013-12-04 ギリアード サイエンシーズ， インコーポレイテッド ｔｏｌｌ様レセプター７の調節因子
WO2008152447A2 (en) 2006-10-30 2008-12-18 The University Of Western Ontario Staphylococcus aureus specific anti-infectives
JP2010519186A (ja) 2007-02-19 2010-06-03 スミスクライン ビーチャム コーポレーション 免疫調節物質としてのプリン誘導体
TW200902018A (en) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Novel adenine compound
BRPI0811125A2 (pt) 2007-05-08 2017-05-09 Astrazeneca Ab imidazoquinolinas com propriedades imunomoduladoras
ES2359123T3 (es) 2007-08-03 2011-05-18 Pfizer Limited Imidazopiridinonas.
WO2009029831A1 (en) 2007-08-31 2009-03-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
JP5380465B2 (ja) 2008-03-03 2014-01-08 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｔｌｒ活性モジュレーターとしての化合物および組成物
SI2276486T1 (sl) 2008-03-24 2014-01-31 4Sc Discovery Gmbh Novi substituirani imidazokinolini
AU2009276403B2 (en) 2008-08-01 2016-03-10 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use
NZ612380A (en) 2008-12-09 2015-01-30 Gilead Sciences Inc Modulators of toll-like receptors
NZ612315A (en) * 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
MY169837A (en) * 2009-06-22 2019-05-16 Wyeth Llc Immunogenic compositions of staphylococcus aureus antigens
CA2768485C (en) 2009-07-16 2018-12-04 Timothy Foster Treatment of staphylococci infections using recombinant fibrinogen binding protein clumping factor a
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
MX2012002723A (es) 2009-09-02 2012-04-11 Novartis Ag Composiciones inmunogenicas que incluyen moduladores de la actividad de receptores tipo toll.
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
WO2011119759A1 (en) 2010-03-23 2011-09-29 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
WO2012031140A1 (en) * 2010-09-01 2012-03-08 Novartis Ag Adsorption of immunopotentiators to insoluble metal salts
EP2680885B8 (en) * 2011-03-02 2018-07-25 GlaxoSmithKline Biologicals SA Combination vaccines with lower doses of antigen and/or adjuvant
US20140363461A1 (en) * 2011-09-01 2014-12-11 Fabio Bagnoli Adjuvanted formulations of staphylococcus aureus antigens
US20150132339A1 (en) * 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
CN104159603A (zh) * 2012-03-08 2014-11-19 诺华股份有限公司 带有tlr4激动剂的联合疫苗
EP2822581A2 (en) * 2012-03-08 2015-01-14 Novartis AG Adjuvanted formulations of dtp booster vaccines
JP2015528457A (ja) * 2012-08-31 2015-09-28 ノバルティス アーゲー Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓに対する免疫化のための安定化されたタンパク質
CN104684570A (zh) * 2012-08-31 2015-06-03 诺华股份有限公司 用于免疫抵抗金黄色葡萄球菌的稳定化的蛋白质
CN104582723A (zh) * 2012-08-31 2015-04-29 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
ES2737024T3 (es) * 2012-08-31 2020-01-09 Glaxosmithkline Biologicals Sa Proteínas estabilizadas para inmunización contra Staphylococcus aureus
CA2882619A1 (en) * 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
GB201219420D0 (en) * 2012-10-29 2012-12-12 Novartis Ag Staphyloccal immunogens
ES2670863T3 (es) * 2013-02-01 2018-06-01 Glaxosmithkline Biologicals Sa Administración intradérmica de composiciones inmunológicas que comprenden agonistas del receptor de tipo Toll
BE1022359B1 (fr) * 2014-03-17 2016-03-25 Glaxosmithkline Biologicals Sa Immunisation contre des infections staphylococciques des os et des articulations
AU2015238512B2 (en) * 2014-03-26 2018-02-01 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
WO2015144691A1 (en) * 2014-03-26 2015-10-01 Glaxosmithkline Biologicals Sa Compositions for immunising against staphylococcus aureus

Also Published As

Publication number Publication date
CA2847204A1 (en) 2013-03-07
IL231104A0 (en) 2014-04-30
RU2014112343A (ru) 2015-10-10
US20140363461A1 (en) 2014-12-11
KR20140066212A (ko) 2014-05-30
WO2013030378A1 (en) 2013-03-07
CN104093418A (zh) 2014-10-08
JP2014525429A (ja) 2014-09-29
EP2763695A1 (en) 2014-08-13
MX2014002363A (es) 2014-04-14
SG11201400210RA (en) 2014-03-28
AU2012300765A1 (en) 2014-03-13
BR112014004782A2 (pt) 2017-03-21

Similar Documents

Publication Publication Date Title
IN2014CN02152A (sl)
ZA201500316B (en) Novel compound with effects of thrombolysis, free radical scavenging and thrombus-targeting as well as preparation method and use thereof
EP2680885B8 (en) Combination vaccines with lower doses of antigen and/or adjuvant
MX2015014500A (es) Terapia de combinacion de anticuerpos contra csf-1r y agonista de tlr9.
IN2014CN03143A (sl)
EP2997246A4 (en) Piston having combustion bowl shaped to balance combustion efficiency and emission properties
EP2992089A4 (en) Use of anti-cd47 agents to enhance immunization
NZ705606A (en) Methods for identifying antibodies with reduced immunogenicity
IL231282A0 (en) Antibodies to 9pcsk and their uses
ZA201404077B (en) Neutralizing antibodies to hiv -1 and their use
ZA201308022B (en) Anti-cd40 antibodies and methods of use
TWD158794S (zh) 遮瑕膏容器
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
BR112014031310A2 (pt) anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
IN2014DN03208A (sl)
EP2726097A4 (en) HERPES VIRUS VACCINE AND METHOD OF USE
WO2014144061A9 (en) Flavivirus neutralizing antibodies and methods of use thereof
EP2950800A4 (en) METHOD AND COMPOSITIONS FOR THE DAILY OPHTHALMIC ADMINISTRATION OF PHENTOLAMINE FOR IMPROVING VISIBILITY
IN2014CN03454A (sl)
WO2013033496A3 (en) Laser adjuvants for enhancing immune response
TWD169462S (zh) 公連接器
EP2726499A4 (en) HEPATITIS B VIRUS SURFACE ANTIGEN EPITOPE AND USE THEREOF
EP2999866A4 (en) One-stroke internal combustion engine
EP2968500A4 (en) VACCINES WITH ONE ANTIGEN AND INTERLEUKIN-23 AS ADJUVANS
EP3010934A4 (en) Antibodies to human resistin